Positron Emission Tomography in Prostate Cancer
- Conditions
- Prostate Cancer
- Registration Number
- NCT00121212
- Lead Sponsor
- Washington University School of Medicine
- Brief Summary
RATIONALE: Diagnostic procedures, such as positron emission tomography using carbon-11 acetate, may help find metastases from prostate cancer and may help predict whether prostate cancer will come back after treatment.
PURPOSE: This clinical trial is studying how well positron emission tomography using carbon-11 acetate works in finding metastases and predicting recurrence in patients with prostate cancer who are at risk for recurrence after treatment.
- Detailed Description
The overall goal of this project is determination of the role of PET in patients with newly diagnosed medium- and high-risk prostate cancer in whom the standard clinical and imaging workup is negative. Thus, the incremental value of PET will be determined in this important group.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 179
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Determine the role of AC-PET in changing initial patient management Completion of patient treatment
- Secondary Outcome Measures
Name Time Method Determine the value of AC-PET in predicting recurrence Minimum of 2 years and maximum of 5 years Assess the performance of AC-PET for detection of lymph node metastasis by comparison with biopsy. Minimum of 2 years and maximum of 5 years
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
🇺🇸Saint Louis, Missouri, United States
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis🇺🇸Saint Louis, Missouri, United States